Clinical trials

What Happens When You Stop Taking Semaglutide

Trial data shows most people regain about two-thirds of lost weight within a year of stopping semaglutide, and blood pressure, cholesterol and blood sugar drift back toward baseline.

Last verified September 14, 2026·17 sources cited·Ozempic Wegovy

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

This is one of the most searched questions about semaglutide, and unusually for this field, there is a clear randomized answer. Two trials were designed specifically to find out. The short version is that most of the weight comes back, gradually, over about a year, and the improvements in blood pressure, cholesterol and blood sugar fade along with it.

That is not a reason to panic, and it is not a moral failing when it happens. It is how the drug works. Here is the evidence, and what it does and does not settle.

What do the trials actually show about stopping?

Two studies answer this directly.

STEP 4 was built as a randomized withdrawal trial. All 803 participants took semaglutide for a 20-week run-in and lost an average of 10.6% of their body weight. Then half were randomly switched to placebo injections while the other half continued semaglutide, and both groups were followed to week 68 [1].

From week 20 to week 68, the continued-semaglutide group lost a further 7.9% of body weight. The placebo-switch group gained 6.9%. The difference between the two was 14.8 percentage points, with a 95% confidence interval of -16.0 to -13.5 [1]. People who kept taking the drug ended the trial around 17.4% below their starting weight. People who stopped were heading back up.

Waist circumference, systolic blood pressure and physical functioning scores all moved in the same directions — better on continued treatment, worse after stopping.

The STEP 1 extension answered a slightly different question: what happens after a full course ends? STEP 1 ran 68 weeks, then stopped both the drug and the structured lifestyle intervention for everybody, and followed 327 participants for another 52 weeks [2].

In this extension group, semaglutide participants had lost 17.3% of their body weight by week 68. Over the following year off treatment, they regained 11.6 percentage points — roughly two-thirds of what they had lost. The net result at week 120 was 5.6% below their original starting weight [2]. The former placebo group regained 1.9 points and ended at 0.1% below baseline.

The extension also tracked cardiometabolic markers. The authors reported that improvements seen from week 0 to week 68 “reverted towards baseline at week 120 for most variables” [2]. Blood pressure, lipids and blood sugar largely followed the weight.

Does the same thing happen with other GLP-1 drugs?

Yes. This is a class effect, not a semaglutide quirk.

SURMOUNT-4 ran the same design with tirzepatide. After a 36-week open-label lead-in producing 20.9% weight loss, 670 people were randomized to continue or switch to placebo for 52 more weeks. The continued group lost a further 5.5%; the placebo group gained 14.0% — a 19.4 percentage point gap. Overall, 89.5% of the continued group maintained at least 80% of their lead-in weight loss, versus 16.6% of the placebo group [3].

A systematic review and meta-analysis published in Obesity Reviews in April 2025 pooled eight randomized trials covering 2,372 participants with a BMI of 27 or higher. Average regain after stopping was 2.20 kg for liraglutide (95% CI 1.69 to 2.70) and 9.69 kg for semaglutide or tirzepatide (95% CI 5.78 to 13.60) [4].

The key finding from that analysis is a pattern rather than a number: regain was proportional to the original loss. The more weight a drug takes off, the more comes back when it stops. The authors’ conclusion was that these medications “should therefore be considered a chronic therapy.”

A larger and more recent synthesis reached the same overall conclusion by a different route. A systematic review and meta-analysis published in The BMJ in January 2026 pooled 37 studies covering 63 treatment arms and 9,341 participants across all weight-management medications. The average rate of regain after stopping was 0.4 kg per month, and every cardiometabolic marker the authors tracked was projected to return to baseline within about 1.4 years [12]. Two details from that paper are worth carrying:

Regain was faster after stopping a medication than after finishing a behavioral weight-management program — by about 0.3 kg per month — and that difference held regardless of how much weight had been lost in the first place.
The authors framed this as a reason for “caution in short term use of these drugs without a more comprehensive approach to weight management.” That is a statement about how the drugs are used in general, not a recommendation for any individual.

Why does the weight come back?

The simple answer is that the drug is doing something while you take it, and stops doing it when you don’t.

Semaglutide is a GLP-1 receptor agonist. It slows how fast the stomach empties and acts on appetite centers in the brain, which reduces hunger and food intake. It does not permanently reset anything. Once the drug clears — semaglutide has a half-life of about a week, so full clearance takes roughly five weeks — the appetite signals it was suppressing come back.

There is a second layer. Substantial weight loss of any kind, drug or otherwise, produces metabolic adaptations that push the body toward regain: resting energy expenditure falls somewhat and hunger hormones shift. That happens after dieting, after surgery and after medication. Stopping a drug that was counteracting those signals leaves them unopposed.

None of this is unique to obesity medicine. Blood pressure rises when antihypertensives stop; cholesterol rises when statins stop. The difference is that weight is visible and carries stigma, so regain gets framed as a personal failure rather than a predictable pharmacology result.

Are there withdrawal symptoms?

The trials did not describe a physical withdrawal syndrome. Stopping semaglutide is not like stopping an opioid or a benzodiazepine, and none of the withdrawal trials reported a discontinuation syndrome as an adverse event.

What people consistently describe is the return of appetite — hunger between meals, larger portion sizes feeling normal again, and what some patients call “food noise” coming back. Because semaglutide clears over about five weeks, that return is typically gradual rather than abrupt.

Any new or concerning symptom after stopping any prescription medication is worth raising with a healthcare provider rather than assuming it is expected.

Does everyone regain the weight?

No, and the averages can be misleading.

The trial figures are group means. Inside those means, some participants maintained most of their loss and others regained everything. Neither trial reported a reliable way to predict which group someone falls into.

Real-world data is consistently less grim than the randomized data, and a 2026 study explains a large part of why.

Researchers at the Cleveland Clinic followed 7,938 adults who started injectable semaglutide or tirzepatide and then stopped within three to twelve months. In the year after stopping, average weight change was +0.5% among those treated for obesity and -1.3% among those treated for type 2 diabetes — nothing like the double-digit regain seen in the withdrawal trials. The reason was not that the pharmacology is different outside a trial. It was that people did not simply stop and do nothing: 19.6% restarted the same drug within the year, and 35.2% received some alternative obesity treatment, including another medication (27.4%), a lifestyle-modification visit (13.7%) or bariatric surgery (0.6%) [13].

The authors were explicit that the group average hides enormous individual variation. Some people in that cohort regained everything; others kept losing.

An Epic Research analysis of electronic health records, which is an industry analysis rather than a peer-reviewed study, reported a similar direction at two years: a majority of people who stopped had maintained their loss or lost more, while a substantial minority had fully regained [14]. Treat that one as supporting context rather than as evidence on the level of the studies above.

Why might real-world results look better than trial results? Partly the treatment switching just described. Partly selection: people who stop in the real world often do so because they reached a goal, whereas trial withdrawal was assigned at random. Partly measurement: people who drop out of care also drop out of the data. And partly because real-world patients who stop often continue other efforts — structured eating, exercise, support programs — that the trial protocols stopped along with the drug. In the STEP 1 extension, notably, the lifestyle intervention was withdrawn at the same time as the medication [2].

Can you do anything to hold onto the loss?

There is no randomized trial that answers this cleanly, which is itself an important finding. Nobody has tested tapering versus abrupt stopping. Nobody has tested a structured maintenance program against usual care after semaglutide discontinuation in a large randomized trial.

What the evidence does support:

Staying on treatment maintains the result. That is the most robust finding across STEP 4, SURMOUNT-4, STEP 5 and SELECT. In STEP 5, weight loss held at 15.2% through two full years of continued treatment [5]. In SELECT, weight loss plateaued around week 65 and stayed flat through week 208 — four years [6].

Dose and persistence drive real-world outcomes more than anything else. A Cleveland Clinic cohort of 7,881 patients found one-year weight loss of 3.6% among people who stopped within three months, 6.8% among those who stopped between three and twelve months, and 11.9% among those who did not stop [7].

Lifestyle support appears to help. Analyses from that same body of work found people who combined semaglutide with a structured lifestyle intervention achieved greater weight loss before discontinuation and kept more of it afterward. The effect sizes were modest, but they pointed consistently in one direction.

What this adds up to in practical terms: if stopping is on the table, it is worth planning for rather than improvising, and worth discussing with the prescriber before the last pen runs out.

How many people stop, and why?

A lot more than the trials would suggest.

In STEP 1, only 4.5% of participants discontinued because of gastrointestinal events [8]. But trial participants get free drug, scheduled visits and a research team. Outside that setting, the picture changes completely.

In an academic obesity clinic cohort, discontinuation reached 14% at three months, 24% at six months, 35% at nine months and 50% at twelve months [9].
A Danish nationwide registry study of all 77,310 adults without diabetes who started semaglutide for weight loss between December 2022 and October 2023 found discontinuation of 18% at three months, 31% at six months, 42% at nine months and 52% at one year. Younger adults and men stopped more often. It was presented at EASD in September 2025 and published in JAMA Network Open in August 2026 [11].
US pharmacy claims data showed one-year persistence with Wegovy of 33.2% for 2021 starters, rising through 34.1% in 2022 and about 40% in 2023 to roughly 59-63% for 2024 starters as supply shortages eased and coverage stabilized [10].

The reasons are rarely purely clinical. Side effects matter, but so do cost, insurance changes, prior authorization renewals, supply problems and the sheer administrative friction of staying on a specialty medication. The steep improvement in persistence from 2021 to 2024 tracks the supply and coverage environment more closely than it tracks anything biological.

Is semaglutide a lifelong medication?

The honest answer is that the evidence points that way, but the evidence is also short.

The longest randomized data is four years, from SELECT. Over that span, weight loss was sustained and cardiovascular events were reduced [6]. Nobody has randomized data at eight years or fifteen years, and nobody knows what happens to someone who takes semaglutide from age 40 to age 70.

What is clear is that the benefits are contingent on continued use. Weight regain follows discontinuation. Cardiometabolic improvements revert. The drug manages a condition rather than curing it. Obesity medicine specialists and the authors of the discontinuation meta-analysis frame it the same way they frame blood pressure or lipid management: chronic treatment for a chronic condition [4].

Whether that framing fits any individual’s life, budget and values is not a question a trial can answer. It is a question to work through with a healthcare provider, ideally before starting rather than after.

What should you ask a healthcare provider about stopping?

Useful questions, if stopping is something you are thinking about:

What is the reason for stopping — side effects, cost, coverage, or having reached a goal — and is there a way to address that reason without stopping?
Is a lower maintenance dose an option instead of stopping entirely? This has not been tested in a randomized trial, but it is a real clinical conversation.
What should be monitored afterward — weight, blood pressure, HbA1c, lipids — and how often?
If weight regain begins, what is the plan? Restarting is possible, and many people do.
If cost or insurance is the driver, are there patient assistance programs, different formulations, or coverage pathways worth exploring first?

Do not stop or change a prescription based on what you read online, here or anywhere else. This page describes what the trials found. Your prescriber knows your situation.

Sources

Questions people ask

How much weight do people regain after stopping semaglutide?

In the STEP 1 trial extension, participants who had lost 17.3% of their body weight regained 11.6 percentage points during the year after treatment stopped — about two-thirds of what they had lost. A pooled meta-analysis of eight trials put average regain at 9.69 kg for semaglutide or tirzepatide.

How fast does the weight come back?

In STEP 4, people switched to placebo gained 6.9% of their body weight over the following 48 weeks, a steady climb rather than a sudden jump. In SURMOUNT-4, the tirzepatide equivalent, the placebo group regained 14.0% over 52 weeks.

Are there withdrawal symptoms when you stop semaglutide?

The trials did not describe a physical withdrawal syndrome. What returns is appetite. Participants in withdrawal trials reported hunger and food preoccupation coming back as the drug cleared, along with weight regain and reversal of blood pressure, cholesterol and blood sugar improvements.

How long does semaglutide stay in your system?

Semaglutide has a half-life of about one week, so it takes roughly five weeks for most of the drug to clear. That is why appetite changes after stopping are gradual rather than immediate.

Does everyone regain the weight?

No. Trial averages hide wide individual variation. A 2026 Cleveland Clinic study of 7,938 people who stopped semaglutide or tirzepatide found average weight change in the following year of only +0.5% in those treated for obesity — but largely because about one in five restarted the drug and about one in three started some other obesity treatment. Individual results varied enormously.

Should you taper off semaglutide instead of stopping abruptly?

There is no randomized trial of tapering. Every withdrawal trial stopped the drug outright. Anyone considering stopping should talk it through with the prescribing healthcare provider rather than deciding on their own.

Is semaglutide meant to be taken forever?

Obesity guidelines and the authors of the discontinuation meta-analysis describe it as chronic therapy, in the same way blood pressure medication is. The FDA labels do not set a stop date. Long-term randomized data extends to four years, from the SELECT trial.

What happens to blood sugar and cholesterol when you stop?

In the STEP 1 extension, most cardiometabolic improvements seen during treatment reverted toward baseline by the time participants were followed to week 120. The benefits track with the weight, not with having once taken the drug.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.